Condition
Recurrent GBM
Total Trials
5
Recruiting
0
Active
0
Completed
1
Success Rate
25.0%-62% vs avg
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
60.0%
3 terminated out of 5 trials
Success Rate
25.0%
-61.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
25% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Terminated3
Completed1
Unknown1
Trial Success Rate
25.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03234595Phase 1CompletedPrimary
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
NCT05370508Phase 1TerminatedPrimary
A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM
NCT04681677Phase 2Terminated
Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab
NCT04763031Not ApplicableTerminated
Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT
NCT03068650UnknownPrimary
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Showing all 5 trials